Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2016 April;107(2) > Minerva Medica 2016 April;107(2):114-22

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints
Cite this article as

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,878


eTOC

 

REVIEWS  


Minerva Medica 2016 April;107(2):114-22

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering

Patrizia ROMUALDI, Sanzio CANDELETTI

Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Bologna, Italy


PDF  


The management of cancer pain presents manifold challenges: even though background pain is adequately controlled, patients frequently experience episodes of acute pain exacerbation known as breakthrough cancer pain (BTcP). The characteristics of BTcP are a rapid onset, a short duration, and a severe intensity. An innovative sublingual fentanyl citrate formulation (Vellofent®) has been developed to target BTcP. The new formulation allows to increase the solubility of fentanyl and to provide optimal oromucosal conditions for rapid drug absorption, thus featuring a shorter time to onset of pain relief (from 6 minutes post-administration).

top of page

Publication History

Cite this article as

Romualdi P, Candeletti S. Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering. Minerva Med 2016 April;107(2):114-22. 

Corresponding author e-mail

patrizia.romualdi@unibo.it